Assuming the worst, AbbVie took an impairment charge a few weeks later of $4 billion as doubts also spread about the other drugs that came in with Rova-T that also used the same cytotoxic agent.

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist Gubra A/S. In addition, there will ...

AbbVie was downgraded to "Hold" due to high debt, fluctuating earnings, and declining Humira sales, but the stock outperformed with a 31% return since July 2024. Despite mixed quarterly results ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development ...